Ischemic stroke and glucose intolerance: A review of the evidence and exploration of novel therapeutic targets

Journal of Pharmacological Sciences

Volumn 118, Issue 1, 2012, Pages 1-13

  Harada, Shinichi ^a   Fujita Hamabe, Wakako ^a   Tokuyama, Shogo ^a  

^a KOBE GAKUIN UNIVERSITY   (Japan)

Author keywords

Cerebral ischemic stress; Glucose intolerance; Insulin; Metformin; Orexin A

Indexed keywords

ADIPONECTIN; ANTIDIABETIC AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CATECHOLAMINE; DABIGATRAN; ERYTHROPOIETIN; GELATINASE A; GELATINASE B; GLUCOSE; INSULIN; LEPTIN; METFORMIN; NORPHENAZONE; OREXIN 1 RECEPTOR; OREXIN A; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); SODIUM GLUCOSE COTRANSPORTER; TISSUE PLASMINOGEN ACTIVATOR; VASCULOTROPIN ANTIBODY;

BLOOD BRAIN BARRIER; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOTHALAMUS VENTROMEDIAL NUCLEUS; INSULIN RESISTANCE; INSULIN SENSITIVITY; MIDDLE CEREBRAL ARTERY OCCLUSION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROGNOSIS; REVIEW; RISK FACTOR;

EID: 84856564434     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.11R04CR     Document Type: Review

References (101)

1. Moskowitz MA, Lo EH, Iadecola C. The science of stroke: mechanisms in search of treatments. Neuron. 2010;67:181-198.
2. Tan JR, Koo YX, Kaur P, Liu F, Armugam A, Wong PT, et al. microRNAs in stroke pathogenesis. Curr Mol Med. 2011;11: 76-92.
3. Davis SM, Lees KR, Albers GW, Diener HC, Markabi S, Karlsson G, et al. Selfotel in acute ischemic stroke: possible neurotoxic effects of an NMDA antagonist. Stroke. 2000;31: 347-354. (Pubitemid 30078164)
4. Shuaib A, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, et al. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med. 2007;357:562-571. (Pubitemid 47236281)
5. Yamaguchi T, Mori E, Minematsu K, Nakagawara J, Hashi K, Saito I, et al. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke. 2006;37:1810-1815. (Pubitemid 44297734)
6. Higashi Y. Edaravone for the treatment of acute cerebral infarction: role of endothelium-derived nitric oxide and oxidative stress. Expert Opin Pharmacother. 2009;10:323-331.
7. Li J, Zeng Z, Viollet B, Ronnett GV, McCullough LD. Neuroprotective effects of adenosine monophosphate-activated protein kinase inhibition and gene deletion in stroke. Stroke. 2007;38: 2992-2999. (Pubitemid 350035695)
8. Goldstein LB, Bushnell CD, Adams RJ, Appel LJ, Braun LT, Chaturvedi S, et al. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011; 42:517-584.
9. Dietrich WD, Alonso O, Busto R. Moderate hyperglycemia worsens acute blood-brain barrier injury after forebrain ischemia in rats. Stroke. 1993;24:111-116. (Pubitemid 23014392)
10. Folbergrova J, Memezawa H, Smith ML, Siesjo BK. Focal and perifocal changes in tissue energy state during middle cerebral artery occlusion in normo- and hyperglycemic rats. J Cereb Blood Flow Metab. 1992;12:25-33.
11. Widmer H, Abiko H, Faden AI, James TL, Weinstein PR. Effects of hyperglycemia on the time course of changes in energy metabolism and pH during global cerebral ischemia and reperfusion in rats: correlation of 1H and 31P NMR spectroscopy with fatty acid and excitatory amino acid levels. J Cereb Blood Flow Metab. 1992;12:456-468.
12. Matz K, Keresztes K, Tatschl C, Nowotny M, Dachenhausenm A, Brainin M, et al. Disorders of glucose metabolism in acute stroke patients: an underrecognized problem. Diabetes Care. 2006;29:792-797. (Pubitemid 44115296)
13. Gray CS, Scott JF, French JM, Alberti KG, O'Connell JE. Prevalence and prediction of unrecognised diabetes mellitus and impaired glucose tolerance following acute stroke. Age Ageing. 2004;33:71-77. (Pubitemid 38111452)
14. Kernan WN, Viscoli CM, Inzucchi SE, Brass LM, Bravata DM, Shulman GI, et al. Prevalence of abnormal glucose tolerance following a transient ischemic attack or ischemic stroke. Arch Intern Med. 2005;165:227-233.
15. Vancheri F, Curcio M, Burgio A, Salvaggio S, Gruttadauria G, Lunetta MC, et al. Impaired glucose metabolism in patients with acute stroke and no previous diagnosis of diabetes mellitus. QJM. 2005;98:871-878. (Pubitemid 43071453)
16. Capes SE, Hunt D, Malmberg K, Pathak P, Gerstein HC. Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke. 2001;32:2426-2432. (Pubitemid 32954818)
17. Vriesendorp TM, Roos YB, Kruyt ND, Biessels GJ, Kappelle LJ, Vermeulen M, et al. Efficacy and safety of two 5 day insulin dosing regimens to achieve strict glycaemic control in patients with acute ischaemic stroke. J Neurol Neurosurg Psychiatry. 2009; 80:1040-1043.
18. Urabe T, Watada H, Okuma Y, Tanaka R, Ueno Y, Miyamoto N, et al. Prevalence of abnormal glucose metabolism and insulin resistance among subtypes of ischemic stroke in Japanese patients. Stroke. 2009;40:1289-1295.
19. Rosso C, Attal Y, Deltour S, Hevia-Montiel N, Lehericy S, Crozier S, et al. Hyperglycemia and the fate of apparent diffusion coefficient-defined ischemic penumbra. AJNR Am J Neuroradiol. 2011;32:852-856.
20. Gentile NT, Seftchick MW, Huynh T, Kruus LK, Gaughan J. Decreased mortality by normalizing blood glucose after acute ischemic stroke. Acad Emerg Med. 2006;13:174-180. (Pubitemid 43155824)
21. Pandolfi A, Giaccari A, Cilli C, Alberta MM, Morviducci L, De Filippis EA, et al. Acute hyperglycemia and acute hyperinsulinemia decrease plasma fibrinolytic activity and increase plasminogen activator inhibitor type 1 in the rat. Acta Diabetol. 2001; 38:71-76. (Pubitemid 33035314)
22. Guyomard V, Jamieson EI, Myint PK. Glucose blood levels as a therapeutic target in acute ischaemic stroke setting. Curr Top Med Chem. 2009;9:1261-1277.
23. Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med. 1995;332: 1351-1362.
24. Chan O, Inouye K, Akirav E, Park E, Riddell MC, Vranic M, et al. Insulin alone increases hypothalamo-pituitary-adrenal activity, and diabetes lowers peak stress responses. Endocrinology. 2005;146:1382-1390. (Pubitemid 40289326)
25. van Kooten F, Hoogerbrugge N, Naarding P, Koudstaal PJ. Hyperglycemia in the acute phase of stroke is not caused by stress. Stroke. 1993;24:1129-1132. (Pubitemid 23237548)
26. Jiao H, Wang Z, Liu Y, Wang P, Xue Y. Specific role of tight junction proteins claudin-5, occludin, and ZO-1 of the bloodbrain barrier in a focal cerebral ischemic insult. J Mol Neurosci. 2011;44:130-139.
27. Yan J, Zhang Z, Shi H. HIF-1 is involved in high glucose-induced paracellular permeability of brain endothelial cells. Cell Mol Life Sci. In press.
28. Wolburg H, Lippoldt A. Tight junctions of the blood-brain barrier: development, composition and regulation. Vascul Pharmacol. 2002;38:323-337. (Pubitemid 36398254)
29. Nitta T, Hata M, Gotoh S, Seo Y, Sasaki H, Hashimoto N, et al. Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. J Cell Biol. 2003;161:653-660. (Pubitemid 36578587)
30. Kumari R, Willing LB, Patel SD, Baskerville KA, Simpson IA. Increased cerebral matrix metalloprotease-9 activity is associated with compromised recovery in the diabetic db/db mouse following a stroke. J Neurochem. 2011;119:1029-1040.
31. Gu Y, Zheng G, Xu M, Li Y, Chen X, Zhu W, et al. Caveolin-1 regulates nitric oxide mediated matrix metalloproteinases activity and blood-brain barrier permeability in focal cerebral ischemia and reperfusion injury. J Neurochem. In press.
32. Zhang Y, Peng F, Gao B, Ingram AJ, Krepinsky JC. High glucose-induced RhoA activation requires caveolae and PKC{beta}1-mediated ROS generation. Am J Physiol Renal Physiol. In press.
33. Takeda S, Sato N, Uchio-Yamada K, Sawada K, Kunieda T, Takeuchi D, et al. Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. Proc Natl Acad Sci U S A. 2010;107:7036-7041.
34. Shichi K, Fujita-Hamabe W, Harada S, Mizoguchi H, Yamada K, Nabeshima T, et al. Involvement of matrix metalloproteinase-mediated proteolysis of neural cell adhesion molecule in the development of cerebral ischemic neuronal damage. J Pharmacol Exp Ther. 2011;338:701-710.
35. Serra-Perez A, Verdaguer E, Planas AM, Santalucia T. Glucose promotes caspase-dependent delayed cell death after a transient episode of oxygen and glucose deprivation in SH-SY5Y cells. J Neurochem. 2008;106:1237-1247.
36. Cronberg T, Rytter A, Asztely F, Soder A, Wieloch T. Glucose but not lactate in combination with acidosis aggravates ischemic neuronal death in vitro. Stroke. 2004;35:753-757. (Pubitemid 38280854)
37. Faraco G, Fossati S, Bianchi ME, Patrone M, Pedrazzi M, Sparatore B, et al. High mobility group box 1 protein is released by neural cells upon different stresses and worsens ischemic neurodegeneration in vitro and in vivo. J Neurochem. 2007; 103:590-603. (Pubitemid 47498027)
38. Diez-Sampedro A, Hirayama BA, Osswald C, Gorboulev V, Baumgarten K, Volk C, et al. A glucose sensor hiding in a family of transporters. Proc Natl Acad Sci U S A. 2003;100:11753-11758. (Pubitemid 37206007)
39. Singh V, Carman M, Roeper J, Bonci A. Brief ischemia causes long-term depression in midbrain dopamine neurons. Eur J Neurosci. 2007;26:1489-1499. (Pubitemid 47416529)
40. Turski L, Huth A, Sheardown M, McDonald F, Neuhaus R, Schneider HH, et al. ZK200775: a phosphonate quinoxalinedione AMPA antagonist for neuroprotection in stroke and trauma. Proc Natl Acad Sci U S A. 1998;95:10960-10965. (Pubitemid 28413176)
41. Vemula S, Roder KE, Yang T, Bhat GJ, Thekkumkara TJ, Abbruscato TJ. A functional role for sodium-dependent glucose transport across the blood-brain barrier during oxygen glucose deprivation. J Pharmacol Exp Ther. 2009;328:487-495.
42. Harada S, Fujita WH, Shichi K, Tokuyama S. The development of glucose intolerance after focal cerebral ischemia participates in subsequent neuronal damage. Brain Res. 2009;1279:174-181.
43. Rask-Madsen C, King GL. Endothelium-dependent delivery of insulin to muscle interstitium. Cell Metab. 2011;13:236-238.
44. Cheng Z, Guo S, Copps K, Dong X, Kollipara R, Rodgers JT, et al. Foxo1 integrates insulin signaling with mitochondrial function in the liver. Nat Med. 2009;15:1307-1311.
45. Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, Sivits G, et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes. 2009;58:250-259.
46. Hanson RW, Reshef L. Regulation of phosphoenolpyruvate carboxykinase (GTP) gene expression. Annu Rev Biochem. 1997; 66:581-611. (Pubitemid 27274668)
47. Postic C, Dentin R, Girard J. Role of the liver in the control of carbohydrate and lipid homeostasis. Diabetes Metab. 2004;30: 398-408. (Pubitemid 39648006)
48. Lin HV, Accili D. Reconstitution of insulin action in muscle, white adipose tissue, and brain of insulin receptor knock-out mice fails to rescue diabetes. J Biol Chem. 2011;286: 9797-9804.
49. Auer RN. Insulin, blood glucose levels, and ischemic brain damage. Neurology. 1998;51:S39-S43. (Pubitemid 28429323)
50. Harada S, Fujita-Hamabe W, Tokuyama S. Effect of orexin-A on post-ischemic glucose intolerance and neuronal damage. J Pharmacol Sci. 2011;115:155-163.
51. De Souza CT, Frederico MJ, da Luz G, Cintra DE, Ropelle ER, Pauli JR, et al. Acute exercise reduces hepatic glucose production through inhibition of the Foxo1/HNF-4alpha pathway in insulin resistant mice. J Physiol. 2010;588:2239-2253.
52. Huang S, Czech MP. The GLUT4 glucose transporter. Cell Metab. 2007;5:237-252. (Pubitemid 46477860)
53. Sauvage M, Maziere P, Fathallah H, Giraud F. Insulin stimulates NHE1 activity by sequential activation of phosphatidylinositol 3-kinase and protein kinase C zeta in human erythrocytes. Eur J Biochem. 2000;267:955-962. (Pubitemid 30108311)
54. Zhao H, Hyde R, Hundal HS. Signalling mechanisms underlying the rapid and additive stimulation of NKCC activity by insulin and hypertonicity in rat L6 skeletal muscle cells. J Physiol. 2004;560:123-136. (Pubitemid 39406021)
55. Aragno M, Parola S, Brignardello E, Mauro A, Tamagno E, Manti R, et al. Dehydroepiandrosterone prevents oxidative injury induced by transient ischemia/reperfusion in the brain of diabetic rats. Diabetes. 2000;49:1924-1931.
56. Spiegelman BM, Flier JS. Obesity and the regulation of energy balance. Cell. 2001;104:531-543. (Pubitemid 32201948)
57. Antuna-Puente B, Feve B, Fellahi S, Bastard JP. Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab. 2008;34:2-11.
58. Ndisang JF. Role of heme oxygenase in inflammation, insulin-signalling, diabetes and obesity. Mediators Inflamm. 2010; 2010:359732.
59. Shimomura I, Hammer RE, Ikemoto S, Brown MS, Goldstein JL. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature. 1999;401:73-76.
60. Matsuzawa Y. Adiponectin: a key player in obesity related disorders. Curr Pharm Des. 2010;16:1896-1901.
61. Yamauchi T, Hara K, Kubota N, Terauchi Y, Tobe K, Froguel P, et al. Dual roles of adiponectin/Acrp30 in vivo as an anti-diabetic and anti-atherogenic adipokine. Curr Drug Targets Immune Endocr Metabol Disord. 2003;3:243-254.
62. Chen MP, Tsai JC, Chung FM, Yang SS, Hsing LL, Shin SJ, et al. Hypoadiponectinemia is associated with ischemic cerebrovascular disease. Arterioscler Thromb Vasc Biol. 2005;25:821-826. (Pubitemid 40463876)
63. Wang YY, Lin SY, Chuang YH, Chen CJ, Tung KC, Sheu WH. Adipose proinflammatory cytokine expression through sympathetic system is associated with hyperglycemia and insulin resistance in a rat ischemic stroke model. Am J Physiol Endocrinol Metab. 2011;300:E155-E163.
64. Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 2005;1:15-25. (Pubitemid 43960587)
65. Ronnett GV, Ramamurthy S, Kleman AM, Landree LE, Aja S. AMPK in the brain: its roles in energy balance and neuroprotection. J Neurochem. 2009;109 Suppl 1:17-23.
66. Hayashi T, Hirshman MF, Kurth EJ, Winder WW, Goodyear LJ. Evidence for 5′ AMP-activated protein kinase mediation of the effect of muscle contraction on glucose transport. Diabetes. 1998;47:1369-1373. (Pubitemid 28357021)
67. Harada S, Fujita-Hamabe W, Tokuyama S. The importance of regulation of blood glucose levels through activation of peripheral 5′-AMP-activated protein kinase on ischemic neuronal damage. Brain Res. 2010;1351:254-263.
68. Yamada T, Katagiri H. Avenues of communication between the brain and tissues/organs involved in energy homeostasis. Endocr J. 2007;54:497-505. (Pubitemid 47414595)
69. Imai J, Katagiri H, Yamada T, Ishigaki Y, Suzuki T, Kudo H, et al. Regulation of pancreatic beta cell mass by neuronal signals from the liver. Science. 2008;322:1250-1254.
70. Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998;92:573-585. (Pubitemid 28101119)
71. Toda C, Shiuchi T, Lee S, Yamato-Esaki M, Fujino Y, Suzuki A, et al. Distinct effects of leptin and a melanocortin receptor agonist injected into medial hypothalamic nuclei on glucose uptake in peripheral tissues. Diabetes. 2009;58:2757-2765.
72. Minokoshi Y, Haque MS, Shimazu T. Microinjection of leptin into the ventromedial hypothalamus increases glucose uptake in peripheral tissues in rats. Diabetes. 1999;48:287-291. (Pubitemid 29061100)
73. Shiuchi T, Nakagami H, Iwai M, Takeda Y, Cui T, Chen R, et al. Involvement of bradykinin and nitric oxide in leptin-mediated glucose uptake in skeletal muscle. Endocrinology. 2001;142: 608-612. (Pubitemid 32222409)
74. Kamohara S, Burcelin R, Halaas JL, Friedman JM, Charron MJ. Acute stimulation of glucose metabolism in mice by leptin treatment. Nature. 1997;389:374-377. (Pubitemid 27415217)
75. Wang JL, Chinookoswong N, Scully S, Qi M, Shi ZQ. Differential effects of leptin in regulation of tissue glucose utilization in vivo. Endocrinology. 1999;140:2117-2124. (Pubitemid 30636450)
76. Nonomura T, Tsuchida A, Ono-Kishino M, Nakagawa T, Taiji M, Noguchi H. Brain-derived neurotrophic factor regulates energy expenditure through the central nervous system in obese diabetic mice. Int J Exp Diabetes Res. 2001;2:201-209.
77. Harada S, Fujita-Hamabe W, Tokuyama S. Ameliorating effect of hypothalamic brain-derived neurotrophic factor against impaired glucose metabolism after cerebral ischemic stress in mice. J Pharmacol Sci. 2012;118:109-116.
78. Kruyt ND, Biessels GJ, Devries JH, Roos YB. Hyperglycemia in acute ischemic stroke: pathophysiology and clinical management. Nat Rev Neurol. 2010;6:145-155.
79. Edaravone Acute Infarction Study Group. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis. 2003;15:222-229.
80. Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribo M, et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation. 2003;107:598-603. (Pubitemid 36176811)
81. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.
82. Diener HC, Connolly SJ, Ezekowitz MD, Wallentin L, Reilly PA, Yang S, et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol. 2010;9:1157-1163.
83. Hori M, Connolly SJ, Ezekowitz MD, Reilly PA, Yusuf S, Wallentin L. Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation -sub-analysis in Japanese population in RE-LY trial. Circ J. 2011;75:800-805.
84. Yamashita T, Kamiya T, Deguchi K, Inaba T, Zhang H, Shang J, et al. Dissociation and protection of the neurovascular unit after thrombolysis and reperfusion in ischemic rat brain. J Cereb Blood Flow Metab. 2009;29:715-725.
85. Lukic-Panin V, Deguchi K, Yamashita T, Shang J, Zhang X, Tian F, et al. Free radical scavenger edaravone administration protects against tissue plasminogen activator induced oxidative stress and blood brain barrier damage. Curr Neurovasc Res. 2010;7:319-329.
86. Kimura K, Aoki J, Sakamoto Y, Kobayashi K, Sakai K, Inoue T, et al. Administration of edaravone, a free radical scavenger, during t-PA infusion can enhance early recanalization in acute stroke patients - A preliminary study. J Neurol Sci. In press.
87. Kanazawa M, Igarashi H, Kawamura K, Takahashi T, Kakita A, Takahashi H, et al. Inhibition of VEGF signaling pathway attenuates hemorrhage after tPA treatment. J Cereb Blood Flow Metab. 2011;31:1461-1474.
88. Zechariah A, ElAli A, Hermann DM. Combination of tissue-plasminogen activator with erythropoietin induces blood-brain barrier permeability, extracellular matrix disaggregation, and DNA fragmentation after focal cerebral ischemia in mice. Stroke. 2010;41:1008-1012.
89. Zhu CZ, Auer RN. Optimal blood glucose levels while using insulin to minimize the size of infarction in focal cerebral ischemia. J Neurosurg. 2004;101:664-668. (Pubitemid 43186427)
90. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103-117.
91. Kahn SE, Lachin JM, Zinman B, Haffner SM, Aftring RP, Paul G, et al. Effects of rosiglitazone, glyburide, and metformin on beta-cell function and insulin sensitivity in ADOPT. Diabetes. 2010;60:1552-1560.
92. He L, Sabet A, Djedjos S, Miller R, Sun X, Hussain MA, et al. Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell. 2009;137: 635-646.
93. Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334: 574-579. (Pubitemid 126537875)
94. Rojas J, Arraiz N, Aguirre M, Velasco M, Bermudez V. AMPK as target for intervention in childhood and adolescent obesity. J Obes. 2011;2011:252817.
95. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-1589.
96. Shiuchi T, Haque MS, Okamoto S, Inoue T, Kageyama H, Lee S, et al. Hypothalamic orexin stimulates feeding-associated glucose utilization in skeletal muscle via sympathetic nervous system. Cell Metab. 2009;10:466-480.
97. Irving EA, Harrison DC, Babbs AJ, Mayes AC, Campbell CA, Hunter AJ, et al. Increased cortical expression of the orexin-1 receptor following permanent middle cerebral artery occlusion in the rat. Neurosci Lett. 2002;324:53-56. (Pubitemid 34442676)
98. Marcus JN, Aschkenasi CJ, Lee CE, Chemelli RM, Saper CB, Yanagisawa M, et al. Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol. 2001;435:6-25. (Pubitemid 32448719)
99. Trivedi P, Yu H, MacNeil DJ, Van der Ploeg LH, Guan XM. Distribution of orexin receptor mRNA in the rat brain. FEBS Lett. 1998;438:71-75. (Pubitemid 28517837)
100. Shimazu T, Ogasawara S. Effects of hypothalamic stimulation on gluconeogenesis and glycolysis in rat liver. Am J Physiol. 1975; 228:1787-1793.
101. Kitamura E, Hamada J, Kanazawa N, Yonekura J, Masuda R, Sakai F, et al. The effect of orexin-A on the pathological mechanism in the rat focal cerebral ischemia. Neurosci Res. 2010; 68:154-157.